- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
COVID-19 Vaccine Updates
COVID-19 Vaccine Updates
As COVID-19 vaccines are distributed, there are complex regulatory and logistical challenges to navigate. In addition, uncertainties around reimbursement, workplace policies and liabilities loom. This online resource is a go-to for staying informed on the COVID-19 vaccines and related legal and regulatory developments.
Please select from our options below related to our links and resources of recent research related to the various rollout initiatives as well as an archive of our routine updates of news headlines and government initiatives related to the same.
Follow us:
Subscribe to receive real-time blog updates via RSS feed. Feeder is only one such tool available, so you may perform a search or consult your technical support team to explore alternatives. King & Spalding does not endorse or provide technical support in connection with any RSS feed reader or browser products, vendors or consultants, and any mention of products or services, or provision of related website links is for informational purposes only. To use the “Feeder” RSS feed reader, you may install an internet browser extension, e.g., for Google Chrome or Microsoft Edge. After install, click the orange RSS icon in your browser menu and continue with or without signing up for a Feeder account. Click the plus + sign to add a feed, then copy and paste our COVID-19 Vaccine Updates blog feed URL - https://www.kslaw.com/blogs/covid-19-vaccine-updates.rss - into the search field. Click Search, then Follow and choose your preferred update and notification settings, then click Done. Click Home to view and access all blog posts. Bookmark the Feeder Home page to quickly return to this page later.
April 30, 2021
Moderna to Make Additional Investments and Produce 3 Billion Vaccine Doses in 2022
Advocacy
April 30, 2021
CDC Says Pfizer and Moderna COVID-19 Vaccines are 94% Effective Against Hospitalization in Older Adults
Executive Briefs
April 30, 2021
CDC Reveals New Guidelines for Fully Vaccinated Individuals
Regulatory Landscape
April 26, 2021
White House COVID-19 Response Team Announces Successful Administration of 200 Million Shots in 100 Days
Health Equity
April 26, 2021
CDC and FDA Lift Recommended Pause on Johnson & Johnson COVID-19 Vaccine
Regulatory Landscape
April 22, 2021
CDC Publishes Two Reports on Post-Vaccination COVID-19 Outbreaks in Skilled Nursing Facilities
Advocacy
April 22, 2021
HHS Launches “We Can Do This: Live” Initiative to Increase COVID-19 Vaccine Confidence
Health Equity
April 21, 2021
EU Exercises Option to Acquire an Additional 100 Million Vaccine Doses from Pfizer and BioNTech
Regulatory Landscape
April 21, 2021
World Bank Provides $2 Billion in Approved Financing for COVID-19 Vaccine Rollout in Developing Countries
Advocacy
April 21, 2021
IRS Announces Employer Tax Credit for COVID-19 Vaccination Paid Time Off
Workforce
April 19, 2021
White House Announces 50 Percent of US Adults Have Received At Least One Dose of a COVID-19 Vaccine
Health Equity
April 16, 2021
CDC and FDA Release Joint Statement on Johnson & Johnson COVID-19 Vaccine
Regulatory Landscape
Contacts
Amy Garrigues
Partner
+1 312 764 6932
Elizabeth Lindquist
Partner
+1 202 626 5585
Steve Cave
Partner
+1 703 245 1017
Mark Polston
Partner
+1 202 626 5540
Amanda Sonneborn
Partner
+1 312 764 6940
David Farber
Partner
+1 202 626 2941
Juliet McBride
Partner
+1 713 276 7448
Chris Kenny
Partner
+1 202 626 9253